PT Kalbe Farma Tbk. (IDX:KLBF)
Indonesia flag Indonesia · Delayed Price · Currency is IDR
920.00
+20.00 (2.22%)
May 8, 2026, 4:10 PM WIB

PT Kalbe Farma Tbk. Balance Sheet

Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
4,392,7004,331,4404,723,2943,232,4213,949,7696,216,248
Short-Term Investments
153,802154,143143,138165,496145,307258,923
Cash & Short-Term Investments
4,546,5024,485,5834,866,4323,397,9174,095,0766,475,171
Cash Growth
-3.03%-7.83%43.22%-17.02%-36.76%19.99%
Accounts Receivable
6,337,3035,651,3354,864,5484,600,1094,613,6233,431,018
Other Receivables
279,211245,037148,612220,032174,145114,125
Receivables
6,616,5145,896,3725,013,1604,820,1414,787,7683,545,143
Inventory
7,414,5546,985,1306,501,6316,942,7677,138,8185,162,583
Prepaid Expenses
143,07945,16945,25337,37231,68630,030
Other Current Assets
1,194,3151,096,080761,192719,527656,882499,283
Total Current Assets
19,914,96418,508,33417,187,66815,917,72416,710,23015,712,210
Property, Plant & Equipment
8,386,8988,429,8018,373,0368,067,0418,054,8878,101,933
Long-Term Investments
541,925530,540517,618450,799384,543303,272
Goodwill
-626,799615,454479,347479,347209,684
Other Intangible Assets
2,279,8151,662,2021,700,2801,298,6851,026,046923,048
Long-Term Deferred Tax Assets
131,949119,839120,349136,103127,49491,862
Other Long-Term Assets
729,686821,833915,323707,870458,766324,628
Total Assets
31,985,23730,699,34829,429,72827,057,56827,241,31325,666,635
Accounts Payable
2,737,3122,402,8001,892,1701,690,7201,996,6151,667,596
Accrued Expenses
1,189,864940,328808,285535,254616,814718,464
Short-Term Debt
110,350112,350269,100120,800705,600-
Current Portion of Long-Term Debt
92690153,813158,217123,70270,000
Current Portion of Leases
22,39921,21317,06821,46526,51723,646
Current Income Taxes Payable
-178,115213,044168,484267,079327,548
Other Current Liabilities
1,539,1251,680,444932,269548,228694,712727,402
Total Current Liabilities
5,599,9765,336,1514,185,7493,243,1694,431,0383,534,656
Long-Term Debt
146,812143,676196,543300,702287,031490,277
Long-Term Leases
25,11220,70225,06320,44224,86842,232
Pension & Post-Retirement Benefits
410,080407,705368,359336,944368,048313,520
Long-Term Deferred Tax Liabilities
68,06362,11163,08035,79032,50019,572
Other Long-Term Liabilities
500500500499.82499.82499.82
Total Liabilities
6,250,5435,970,8454,839,2943,937,5465,143,9854,400,757
Common Stock
468,134468,134468,751468,751468,751468,751
Retained Earnings
26,371,60125,342,67423,313,47821,506,77220,497,73918,746,849
Treasury Stock
-2,258,619-2,214,631-1,462,395-1,003,973-1,003,973-2,063
Comprehensive Income & Other
-283,858-283,720469,046447,306422,701365,989
Total Common Equity
24,297,25823,312,45722,788,88021,418,85720,385,21819,579,526
Minority Interest
1,437,4361,416,0461,801,5541,701,1661,712,1101,686,352
Shareholders' Equity
25,734,69424,728,50324,590,43423,120,02222,097,32821,265,878
Total Liabilities & Equity
31,985,23730,699,34829,429,72827,057,56827,241,31325,666,635
Total Debt
305,599298,842561,587621,6271,167,718626,155
Net Cash (Debt)
4,240,9034,186,7414,304,8452,776,2902,927,3585,849,016
Net Cash Growth
2.08%-2.74%55.06%-5.16%-49.95%38.00%
Net Cash Per Share
93.3891.9793.2060.0262.93124.78
Filing Date Shares Outstanding
45,24945,28745,95146,25646,25646,873
Total Common Shares Outstanding
45,24945,28745,95146,25646,25646,873
Working Capital
14,314,98813,172,18313,001,91912,674,55612,279,19112,177,553
Book Value Per Share
536.97514.78495.93463.05440.71417.71
Tangible Book Value
22,017,44321,023,45620,473,14619,640,82418,879,82418,446,795
Tangible Book Value Per Share
486.59464.23445.54424.61408.16393.55
Land
-1,571,3341,662,8211,638,7561,636,8831,661,011
Buildings
-4,973,2544,920,2194,848,1734,784,3424,337,522
Machinery
-7,322,0516,834,3306,349,1246,007,5125,486,798
Construction In Progress
-1,015,228852,218534,552398,386682,852
Leasehold Improvements
-307,026266,543260,791231,605204,081
Source: S&P Global Market Intelligence. Standard template. Financial Sources.